AU2021297249A1 - Compositions and methods for treating obsessive-compulsive disorder - Google Patents

Compositions and methods for treating obsessive-compulsive disorder Download PDF

Info

Publication number
AU2021297249A1
AU2021297249A1 AU2021297249A AU2021297249A AU2021297249A1 AU 2021297249 A1 AU2021297249 A1 AU 2021297249A1 AU 2021297249 A AU2021297249 A AU 2021297249A AU 2021297249 A AU2021297249 A AU 2021297249A AU 2021297249 A1 AU2021297249 A1 AU 2021297249A1
Authority
AU
Australia
Prior art keywords
dosage form
patient
troriluzole
week
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021297249A
Other languages
English (en)
Inventor
Loren AGUIAR
Robert Berman
Vladimir Coric
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of AU2021297249A1 publication Critical patent/AU2021297249A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021297249A 2020-06-24 2021-06-24 Compositions and methods for treating obsessive-compulsive disorder Pending AU2021297249A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043681P 2020-06-24 2020-06-24
US63/043,681 2020-06-24
PCT/US2021/038789 WO2021262914A1 (en) 2020-06-24 2021-06-24 Compositions and methods for treating obsessive-compulsive disorder

Publications (1)

Publication Number Publication Date
AU2021297249A1 true AU2021297249A1 (en) 2023-02-23

Family

ID=79281806

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021297249A Pending AU2021297249A1 (en) 2020-06-24 2021-06-24 Compositions and methods for treating obsessive-compulsive disorder

Country Status (12)

Country Link
US (1) US20230181541A1 (https=)
EP (1) EP4171554A4 (https=)
JP (1) JP7805969B2 (https=)
KR (1) KR20230027189A (https=)
CN (1) CN115968312A (https=)
AU (1) AU2021297249A1 (https=)
BR (1) BR112022025901A2 (https=)
CA (1) CA3187323A1 (https=)
IL (1) IL299301A (https=)
MX (1) MX2022016174A (https=)
PH (1) PH12022553441A1 (https=)
WO (1) WO2021262914A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2400349A1 (hu) * 2024-07-05 2026-01-28 Egis Gyógyszergyár Zrt. Troriluzole-hidroklorid-sók

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564187T3 (es) * 2005-04-05 2016-03-18 Yale University Agentes de modulación de glutamato en el tratamiento de trastornos mentales
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用
TW202000205A (zh) * 2018-02-21 2020-01-01 美商Ａｉ治療公司 使用阿吡莫德與麩胺酸性劑的組合治療
MX2020012377A (es) * 2018-05-27 2021-04-12 Biohaven Therapeutics Ltd Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
MX2021000515A (es) * 2018-07-22 2021-06-08 Biohaven Therapeutics Ltd Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
US20210315865A1 (en) * 2018-08-16 2021-10-14 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases

Also Published As

Publication number Publication date
BR112022025901A2 (pt) 2023-01-10
WO2021262914A1 (en) 2021-12-30
IL299301A (en) 2023-02-01
EP4171554A1 (en) 2023-05-03
US20230181541A1 (en) 2023-06-15
PH12022553441A1 (en) 2024-03-04
MX2022016174A (es) 2023-01-24
CA3187323A1 (en) 2021-12-30
CN115968312A (zh) 2023-04-14
KR20230027189A (ko) 2023-02-27
JP2023531919A (ja) 2023-07-26
JP7805969B2 (ja) 2026-01-26
EP4171554A4 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
US20220152054A1 (en) Methods and compositions for treating various disorders
US11554117B2 (en) Glutamate agents in the treatment of mental disorders
Grant et al. A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response
Weihs et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression
JP2024543053A (ja) 神経変性疾患の治療のための胆汁酸及びフェニルブチレート化合物の組合せ
by Gabapentin A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin
US20230181541A1 (en) Compositions and methods for treating obsessive-compulsive disorder
US20220401391A1 (en) Methods and compositions for treating pain
WO2024054412A1 (en) Methods and compositions for treating amyotrophic lateral sclerosis
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
Frye et al. Antiepileptics in the Treatment of Alcohol Withdrawal and Alcohol Use Relapse Prevention
Mak The diagnosis and management of obsessive compulsive disorders in primary care
Femández-Novoa et al. Whole blood and serum histamine in healthy subjects and in schizophrenic patients: Correlation analysis with transcranial Doppler ultrasonography